#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
US employers pulling GLP-1 coverage in 2027
About 14% of large US employers have dropped or plan to drop GLP-1 obesity drug coverage in 2027, as pharmacy costs hit 25% of total healthcare spend.
Zepbound cost savings; ivonescimab biliary
A matched cohort study finds Zepbound users over 55 spent up to $607 less per month by month 12; ivonescimab shows a survival benefit in biliary cancer.
Lilly's Medicare GLP-1 push: what changed
Lilly's 'A Life Covered' campaign targets the Medicare Part D exclusion for obesity drugs. Here is what the campaign asks for and what has already shifted.
Lilly obesity campaign and GLP-1 access
Lilly's new obesity campaign brings older adults into view as CMS prepares a limited Medicare GLP-1 access demonstration.
Semaglutide: body composition at 12 months
A 2026 Obesity Facts study followed 83 adults for 12 months. Semaglutide cut more weight, improved muscle quality scores, and preserved handgrip strength.
Oral semaglutide nanomicelles in mice
A mouse study tests dual-transporter-targeted semaglutide nanomicelles. The early result is about delivery science, not a new treatment.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
GLP-1 drugs: eye and mood safety signals
A new pharmacovigilance study flags eye and psychiatric signals with semaglutide. Here is what it found, and what regulators already concluded.
GLP-1 drugs in IIH: what research shows
A 2026 Headache meta-analysis finds GLP-1 receptor agonists reduce intracranial pressure and headache days in IIH. What the data shows.
Semaglutide gut transit: a 13C breath test
A 13C-mannitol breath test now tracks semaglutide gut transit delay in mice, noninvasively. Here is what the method reveals about GLP-1 effects on motility.